Avalo TherapeuticsAVTX
13F holders, Q2 2025 (June 30)36holders +2
4new positions
2sold out
$4.99avg. 13F price*
At the end of Q2 2025, 36 institutions reported holding Avalo Therapeutics Inc. (AVTX) in their 13F filings, up 2 from Q1 2025. 4 opened new positions and 2 sold out. The largest holders were BVF Inc. ($5.1M), Nantahala Capital Management, LLC ($5.0M) and Orbimed Advisors LLC ($4.8M).
- Company
- Avalo Therapeutics Inc.
- CUSIP
- 05338F306
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $176K |
| Exits | 2 | $84K |
All 13F filers, Q1 2025 → Q2 2025: 694,742 shares bought and 1,106,759 shares sold, net −412,017 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 36 holders
| BVF Inc. | 0.18% | Reduce -0.8% | 1,028,049 | $5.1M |
| Nantahala Capital Management, LLC | 0.35% | Add +10.6% | 995,000 | $5.0M |
| Orbimed Advisors LLC | 0.12% | No change | 967,000 | $4.8M |
| Ra Capital Management, L.P. | 0.08% | Reduce -3.5% | 932,973 | $4.7M |
| Affinity Asset Advisors, LLC | 0.47% | Reduce -7.5% | 607,872 | $3.0M |
| Deep Track Capital, LP | 0.09% | Reduce -34.0% | 567,103 | $2.8M |
| TCG Crossover Management, LLC | 0.28% | No change | 483,000 | $2.4M |
| Commodore Capital LP | 0.17% | No change | 483,000 | $2.4M |
| Bank of America Corp. | 0.00% | Add +7066.8% | 406,571 | $2.0M |
| Rwa Wealth Partners, LLC | 0.02% | Reduce -16.6% | 261,016 | $1.3M |
| Vanguard Group Inc. | 0.00% | No change | 166,941 | $833K |
| BlackRock, Inc. | 0.00% | Add +16.6% | 155,899 | $778K |
| Velan Capital Investment Management LP | 0.77% | Add +38.4% | 154,972 | $773K |
| Perceptive Advisors LLC | 0.03% | Reduce -73.1% | 139,667 | $697K |
| Geode Capital Management, LLC | 0.00% | Add +2.5% | 110,460 | $552K |
| ADAR1 Capital Management, LLC | 0.09% | Add +947.3% | 104,730 | $523K |
| UBS Group AG | 0.00% | Reduce -15.4% | 83,724 | $418K |
| Sio Capital Management, LLC | 0.14% | Add +1.0% | 72,173 | $360K |
| Ikarian Capital, LLC | 0.06% | Reduce -82.3% | 35,300 | $176K |
| Northern Trust Corp. | 0.00% | No change | 22,673 | $113K |
| Walleye Capital LLC | 0.00% | Add +1.9% | 20,613 | $103K |
| Two Sigma Investments, LP | 0.00% | New | 12,889 | $64K |
| Boothbay Fund Management, LLC | 0.00% | New | 11,321 | $56K |
| Quadrature Capital Ltd | 0.00% | New | 10,976 | $55K |
| Allostery Investments LP | 0.57% | Reduce -91.6% | 9,000 | $45K |
| JPMorgan Chase & Co. | 0.00% | Reduce -93.3% | 74 | $369 |
| SBI Securities Co., Ltd. | 0.00% | No change | 22 | $110 |
| Morgan Stanley | 0.00% | Reduce -97.2% | 10 | $50 |
| BNP Paribas Financial Markets | 0.00% | Add +25.0% | 5 | $25 |
| Osaic Holdings, Inc. | 0.00% | No change | 2 | $8 |
| Raymond James Financial Inc. | 0.00% | New | 1 | $5 |
| Group One Trading LLC | 0.00% | Reduce -50.0% | 1 | $5 |
| Parallel Advisors, LLC | 0.00% | No change | 1 | $5 |
| Key Financial Inc | 0.00% | No change | 1 | $5 |
| Activest Wealth Management | 0.00% | No change | 1 | $5 |
| Avion Wealth | 0.00% | No change | 5 | $0 |
"% of holder's portfolio" is AVTX's weight in each manager's 13F, not the share of Avalo Therapeutics Inc. the manager owns.